CA2345642A1 - Procedes pour traiter les troubles non thyroidiens - Google Patents
Procedes pour traiter les troubles non thyroidiens Download PDFInfo
- Publication number
- CA2345642A1 CA2345642A1 CA002345642A CA2345642A CA2345642A1 CA 2345642 A1 CA2345642 A1 CA 2345642A1 CA 002345642 A CA002345642 A CA 002345642A CA 2345642 A CA2345642 A CA 2345642A CA 2345642 A1 CA2345642 A1 CA 2345642A1
- Authority
- CA
- Canada
- Prior art keywords
- igf
- igfbp
- thyroid
- disorder
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 208000024799 Thyroid disease Diseases 0.000 title claims abstract description 28
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims abstract description 113
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims abstract description 113
- 210000001685 thyroid gland Anatomy 0.000 claims abstract description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- 208000024891 symptom Diseases 0.000 claims abstract description 30
- 239000000556 agonist Substances 0.000 claims abstract description 29
- 239000005557 antagonist Substances 0.000 claims abstract description 25
- 230000001419 dependent effect Effects 0.000 claims abstract description 11
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 109
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 94
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 76
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims description 21
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims description 21
- 102000013275 Somatomedins Human genes 0.000 claims description 18
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 12
- 102000057148 human IGFBP3 Human genes 0.000 claims description 12
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 8
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims description 6
- 102000011923 Thyrotropin Human genes 0.000 claims description 6
- 108010061174 Thyrotropin Proteins 0.000 claims description 6
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 claims description 5
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims description 5
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims description 5
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 claims description 5
- 230000004075 alteration Effects 0.000 claims description 4
- 229960002662 propylthiouracil Drugs 0.000 claims description 4
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims description 3
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001704 carbimazole Drugs 0.000 claims description 3
- 102000044162 human IGF1 Human genes 0.000 claims description 3
- 229950008325 levothyroxine Drugs 0.000 claims description 3
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002178 thiamazole Drugs 0.000 claims description 3
- 102100032251 Pro-thyrotropin-releasing hormone Human genes 0.000 claims 2
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 106
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 106
- 208000035475 disorder Diseases 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 206010020850 Hyperthyroidism Diseases 0.000 description 13
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 11
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 239000005495 thyroid hormone Substances 0.000 description 10
- 229940036555 thyroid hormone Drugs 0.000 description 10
- 230000035772 mutation Effects 0.000 description 8
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102000004217 thyroid hormone receptors Human genes 0.000 description 7
- 108090000721 thyroid hormone receptors Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 208000003532 hypothyroidism Diseases 0.000 description 6
- 230000002989 hypothyroidism Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001228 trophic effect Effects 0.000 description 6
- 108010034949 Thyroglobulin Proteins 0.000 description 5
- 102000009843 Thyroglobulin Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 229960002175 thyroglobulin Drugs 0.000 description 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 102200099125 rs137853176 Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 235000002374 tyrosine Nutrition 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010028665 Myxoedema Diseases 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015861 cell surface binding Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 208000003786 myxedema Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101100479039 Caenorhabditis elegans aars-1 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010057040 Temperature intolerance Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- -1 aromatic amino acids Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical class NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 108010053474 thyroactive iodinated casein Proteins 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010018265 Gigantism Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- LKYWLLWWYBVUPP-XOCLESOZSA-L Liotrix Chemical compound [Na+].[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1.IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 LKYWLLWWYBVUPP-XOCLESOZSA-L 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010060819 Myxoedema coma Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000015875 Pituitary gigantism Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- UBAQSAUDKMIEQZ-QWRGUYRKSA-N Tyr-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UBAQSAUDKMIEQZ-QWRGUYRKSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 108010017068 histidyl-proline diketopiperazine Proteins 0.000 description 1
- LCXWQHWWTPOAFI-UWVGGRQHSA-N histidylproline diketopiperazine Chemical compound C([C@@H]1NC([C@@H]2CCCCN2C1=O)=O)C1=CN=CN1 LCXWQHWWTPOAFI-UWVGGRQHSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000003045 protirelin derivative Substances 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des procédés permettant de traiter les troubles non thyroïdiens qui répondent à IGF, à IGFBP-3, ou qui sont indépendants de IGF. Les agonistes du tronc thyro-cervical et IGF sont administrés à des sujets souffrant de troubles non thyroïdiens répondant à IGF, afin d'atténuer les symptômes de ces troubles. Les antagonistes du tronc thyro-cervical et IGFBP-3 sont administrés à des sujets souffrant de troubles non thyroïdiens répondant à IGFBP-3, afin d'atténuer les symptômes de ces troubles. Enfin, les antagonistes du tronc thyro-cervical sont administrés aux sujets souffrant de troubles non thyroïdiens dépendants de IGF, afin d'atténuer les symptômes de ces troubles.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10279098P | 1998-10-02 | 1998-10-02 | |
US39913499A | 1999-09-20 | 1999-09-20 | |
US09/399,134 | 1999-09-20 | ||
US60/102,790 | 1999-09-20 | ||
PCT/US1999/022761 WO2000020024A2 (fr) | 1998-10-02 | 1999-09-29 | Procedes pour traiter les troubles non thyroidiens |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2345642A1 true CA2345642A1 (fr) | 2000-04-13 |
Family
ID=26799734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002345642A Abandoned CA2345642A1 (fr) | 1998-10-02 | 1999-09-29 | Procedes pour traiter les troubles non thyroidiens |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1117425A2 (fr) |
JP (1) | JP2002526417A (fr) |
AU (1) | AU6407099A (fr) |
CA (1) | CA2345642A1 (fr) |
WO (1) | WO2000020024A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001291090B2 (en) | 2000-09-19 | 2007-05-10 | Bioexpertise, Llc | Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
EP2065038A1 (fr) | 2007-11-30 | 2009-06-03 | Pharnext | Nouvelles approches thérapeutiques pour traiter la maladie de Charcot-Marie-Tooth |
EP2135607A1 (fr) | 2008-06-18 | 2009-12-23 | Pharnext | Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2263665A1 (fr) | 2009-06-02 | 2010-12-22 | Pharnext | Nouvelles compositions pour traiter le CMT et troubles associés |
SI3003268T1 (sl) | 2013-06-05 | 2019-01-31 | Pharnext | Stabilne oralne raztopine za kombinirane API |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
WO2019098811A2 (fr) * | 2017-11-20 | 2019-05-23 | 주식회사 노브메타파마 | Composition pour prévenir, soulager ou traiter des maladies de perte osseuse, comprenant cyclo(his-pro) (chp) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818531A (en) * | 1985-02-06 | 1989-04-04 | Eli Lilly And Company | Growth hormone and thyroid hormone |
US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
MD1486G2 (ro) * | 1992-10-29 | 2001-11-30 | Genentech, Inc. | Metodă de tratament sau profilaxie a obezităţii |
US5310742A (en) * | 1992-11-30 | 1994-05-10 | Elias Alan N | Uses for thioureylenes |
EP0726911B1 (fr) * | 1993-09-20 | 2002-10-30 | Celtrix Pharmaceuticals, Inc. | Traitement de troubles hematologiques a l'aide d'un complexe des igf-1/igfbp-3 |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
-
1999
- 1999-09-29 WO PCT/US1999/022761 patent/WO2000020024A2/fr not_active Application Discontinuation
- 1999-09-29 AU AU64070/99A patent/AU6407099A/en not_active Abandoned
- 1999-09-29 EP EP99951681A patent/EP1117425A2/fr not_active Withdrawn
- 1999-09-29 CA CA002345642A patent/CA2345642A1/fr not_active Abandoned
- 1999-09-29 JP JP2000573383A patent/JP2002526417A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2000020024A2 (fr) | 2000-04-13 |
WO2000020024A3 (fr) | 2000-07-06 |
EP1117425A2 (fr) | 2001-07-25 |
JP2002526417A (ja) | 2002-08-20 |
AU6407099A (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0571417B1 (fr) | Combinaison d'igf-i et d'igfbp pour favoriser l'anabolisme | |
EP0331630B1 (fr) | Utilisation d' IGF-I pour la fabrication d'une préparation destinée au traitement et la prévention des effets secondaires de l' hyperinsulinémie chez les diabétiques traités à l'insulinè | |
US5681814A (en) | Formulated IGF-I Composition | |
EP0613376B1 (fr) | Utilisation du igf-1 | |
Tönshoff et al. | Derangements of the somatotropic hormone axis in chronic renal failure. | |
EP0918536A1 (fr) | Composition contenant de l'insuline et le facteur de croissasnce de substances apparentees a l'insuline (igf-i) | |
AU1098295A (en) | Method of treating renal disease by administering igf-i and igfbp-3 | |
Simpson et al. | Insulin-like growth factor-I and diabetes. A review | |
Rabkin et al. | Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure | |
AU755897B2 (en) | Methods of Increasing Sex Hormone Binding Globulin (SHBG) in a Subject | |
Kovács et al. | Growth promoting effects of growth hormone and IGF-I are additive in experimental uremia | |
CA2345642A1 (fr) | Procedes pour traiter les troubles non thyroidiens | |
EP1117424B1 (fr) | Igf inactif aux fins du traitement du cancer | |
Höybye | Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: challenging issues, benefits, and risks | |
US5948757A (en) | High dose IGF-1 therapy | |
Kovacs et al. | Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect? | |
Quin | The insulin-like growth factors | |
US7288516B1 (en) | Null IGF for the treatment of cancer | |
GUEVARA-AGUIRRE | RON G. ROSENFELD, ARLAN L. ROSENBLOOM, AND JAIME GUEVARA-AGUIRRE | |
Rosenfeld et al. | Use of Recombinant IGF-I in Syndromes of GH Insensitivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |